RENATO FRAGA RIGHETTI
Projetos de Pesquisa
Unidades Organizacionais
LIM/20 - Laboratório de Terapêutica Experimental, Hospital das Clínicas, Faculdade de Medicina
20 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 20
- Extracellular Matrix Component Remodeling in Respiratory Diseases: What Has Been Found in Clinical and Experimental Studies?(2019) ITO, Juliana T.; LOURENCO, Juliana D.; RIGHETTI, Renato F.; TIBERIO, Iolanda F. L. C.; PRADO, Carla M.; LOPES, Fernanda D. T. Q. S.Changes in extracellular matrix (ECM) components in the lungs are associated with the progression of respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome (ARDS). Experimental and clinical studies have revealed that structural changes in ECM components occur under chronic inflammatory conditions, and these changes are associated with impaired lung function. In bronchial asthma, elastic and collagen fiber remodeling, mostly in the airway walls, is associated with an increase in mucus secretion, leading to airway hyperreactivity. In COPD, changes in collagen subtypes I and III and elastin, interfere with the mechanical properties of the lungs, and are believed to play a pivotal role in decreased lung elasticity, during emphysema progression. In ARDS, interstitial edema is often accompanied by excessive deposition of fibronectin and collagen subtypes I and III, which can lead to respiratory failure in the intensive care unit. This review uses experimental models and human studies to describe how inflammatory conditions and ECM remodeling contribute to the loss of lung function in these respiratory diseases.
- Evidences of Herbal Medicine-Derived Natural Products Effects in Inflammatory Lung Diseases(2016) SANTANA, Fernanda Paula R.; PINHEIRO, Nathalia M.; MERNAK, Marcia Isabel B.; RIGHETTI, Renato F.; MARTINS, Milton A.; LAGO, Joao H. G.; LOPES, Fernanda D. T. Q. dos Santos; TIBERIO, Iolanda F. L. C.; PRADO, Carla M.Pulmonary inflammation is a hallmark of many respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and acute respiratory syndrome distress (ARDS). Most of these diseases are treated with anti-inflammatory therapy in order to prevent or to reduce the pulmonary inflammation. Herbal medicine-derived natural products have been used in folk medicine and scientific studies to evaluate the value of these compounds have grown in recent years. Many substances derived from plants have the biological effects in vitro and in vivo, such as flavonoids, alkaloids, and terpenoids. Among the biological activities of natural products derived from plants can be pointed out the anti-inflammatory, antiviral, antiplatelet, antitumor anti-allergic activities, and antioxidant. Although many reports have evaluated the effects of these compounds in experimental models, studies evaluating clinical trials are scarce in the literature. This review aims to emphasize the effects of these different natural products in pulmonary diseases in experimental models and in humans and pointing out some possible mechanisms of action.
- Effects of environmental exposure to iron powder in an elastase mice model(2022) GALLI, T. Tafarel; CAMPOS, E. C.; SANTOS, T. M.; FUKUZAKI, S.; CAMARGO, L. N.; BEZERRA, S. K. M.; HAMAGUCHI, S. S. S.; SILVA, F. J. A. Da; SARAIVA-ROMANHOLO, B. M.; OLIVO, C. R.; PRADO, C. M.; LOPES, F. Degobbi Tenorio Quirino Dos Santos; LEICK, E. A.; BOUROTTE, C. L. M.; BENSENOR, I. J. M.; LOTUFO, P. A.; RIGHETTI, R. F.; TIBERIO, I. F. L. C.
- iNOS Inhibition Reduces Lung Mechanical Alterations and Remodeling Induced by Particulate Matter in Mice(2019) PRADO, Carla Maximo; RIGHETTI, Renato Fraga; LOPES, Fernanda Degobbi Tenorio Quirino dos Santos; LEICK, Edna Aparecida; ARANTES-COSTA, Fernanda Magalhaes; ALMEIDA, Francine Maria de; SALDIVA, Paulo Hilario Nascimento; MAUAD, Thais; TIBERIO, Iolanda de Fatima Lopes Calvo; MARTINS, Milton de ArrudaBackground. The epidemiologic association between pulmonary exposure to ambient particulate matter (PM) and acute lung damage is well known. However, the mechanism involved in the effects of repeated exposures of PM in the lung injury is poorly documented. This study tested the hypotheses that chronic nasal instillation of residual oil fly ash (ROFA) induced not only distal lung and airway inflammation but also remodeling. In addition, we evaluated the effects of inducible nitric oxide inhibition in these responses. For this purpose, airway and lung parenchyma were evaluated by quantitative analysis of collagen and elastic fibers, immunohistochemistry for macrophages, neutrophils, inducible nitric oxide synthase (iNOS), neuronal nitric oxide synthase (nNOS), and alveolar septa 8-iso prostaglandin F2 (8-iso-PGF-2) detection. Anesthetized in vivo (airway resistance, elastance, H, G, and Raw) respiratory mechanics were also analyzed. C57BL6 mice received daily 60ul of ROFA (intranasal) for five (ROFA-5d) or fifteen days (ROFA-15d). Controls have received saline (SAL). Part of the animals has received 1400W (SAL+1400W and ROFA-15d+1400W), an iNOS inhibitor, for four days before the end of the protocol. A marked neutrophil and macrophage infiltration and an increase in the iNOS, nNOS, and 8-iso-PGF2 expression was observed in peribronchiolar and alveolar wall both in ROFA-5d and in ROFA-15d groups. There was an increment of the collagen and elastic fibers in alveolar and airway walls in ROFA-15d group. The iNOS inhibition reduced all alterations induced by ROFA, except for the 8-iso-PGF2 expression. In conclusion, repeated particulate matter exposures induce extracellular matrix remodeling of airway and alveolar walls, which could contribute to the pulmonary mechanical changes observed. The mechanism involved is, at least, dependent on the inducible nitric oxide activation.
- Investigating the Effects of a New Peptide, Derived from the Enterolobium contortisiliquum Proteinase Inhibitor (EcTI), on Inflammation, Remodeling, and Oxidative Stress in an Experimental Mouse Model of Asthma-Chronic Obstructive Pulmonary Disease Overlap (ACO)(2023) BARBOSA, Jessica Anastacia Silva; SILVA, Luana Laura Sales da; JOAO, Juliana Morelli Lopes Goncalves; CAMPOS, Elaine Cristina de; FUKUZAKI, Silvia; CAMARGO, Leandro do Nascimento; SANTOS, Tabata Maruyama dos; SANTOS, Henrique Tibucheski dos; BEZERRA, Suellen Karoline Moreira; SARAIVA-ROMANHOLO, Beatriz Mangueira; LOPES, Fernanda Degobbi Tenorio Quirino dos Santos; BONTURI, Camila Ramalho; OLIVA, Maria Luiza Vilela; LEICK, Edna Aparecida; RIGHETTI, Renato Fraga; TIBERIO, Iolanda de Fatima Lopes CalvoThe synthesized peptide derived from Enterolobium contortisiliquum (pep3-EcTI) has been associated with potent anti-inflammatory and antioxidant effects, and it may be a potential new treatment for asthma-COPD overlap-ACO). Purpose: To investigate the primary sequence effects of pep3-EcTI in an experimental ACO. BALB/c mice were divided into eight groups: SAL (saline), OVA (ovalbumin), ELA (elastase), ACO (ovalbumin + elastase), ACO-pep3-EcTI (treated with inhibitor), ACO-DX (treated with dexamethasone), ACO-DX-pep3-EcTI (treated with dexamethasone and inhibitor), and SAL-pep3-EcTI (saline group treated with inhibitor). We evaluated the hyperresponsiveness to methacholine, exhaled nitric oxide, bronchoalveolar lavage fluid (BALF), mean linear intercept (Lm), inflammatory markers, tumor necrosis factor (TNF-alpha), interferon (IFN)), matrix metalloproteinases (MMPs), growth factor (TGF-beta), collagen fibers, the oxidative stress marker inducible nitric oxide synthase (iNOS), transcription factors, and the signaling pathway NF-kappa B in the airways (AW) and alveolar septa (AS). Statistical analysis was conducted using one-way ANOVA and t-tests, significant when p < 0.05. ACO caused alterations in the airways and alveolar septa. Compared with SAL, ACO-pep3-EcTI reversed the changes in the percentage of resistance of the respiratory system (%Rrs), the elastance of the respiratory system (%Ers), tissue resistance (%Gtis), tissue elastance (%Htis), airway resistance (%Raw), Lm, exhaled nitric oxide (ENO), lymphocytes, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17, TNF-alpha, INF-gamma, MMP-12, transforming growth factor (TGF)-beta, collagen fibers, and iNOS. ACO-DX reversed the changes in %Rrs, %Ers, %Gtis, %Htis, %Raw, total cells, eosinophils, neutrophils, lymphocytes, macrophages, IL-1 beta, IL-6, IL-10, IL-13, IL-17, TNF-alpha, INF-gamma, MMP-12, TGF-beta, collagen fibers, and iNOS. ACO-DX-pep3-EcTI reversed the changes, as was also observed for the pep3-EcTI and the ACO-DX-pep3-EcTI. Significance: The pep3-EcTI was revealed to be a promising strategy for the treatment of ACO, asthma, and COPD.
- Bronchial Vascular Remodeling Is Attenuated by Anti-IL-17 in Asthmatic Responses Exacerbated by LPS(2020) CAMARGO, Leandro do Nascimento; SANTOS, Tabata Maruyama dos; ANDRADE, Felipp Costa Pinto de; FUKUZAKI, Silvia; LOPES, Fernanda Degobbi Tenorio Quirino dos Santos; MARTINS, Milton de Arruda; PRADO, Carla Maximo; LEICK, Edna Aparecida; RIGHETTI, Renato Fraga; TIBERIO, Iolanda de Fatima Lopes CalvoIntroduction Although the major alterations associated with asthma are related to the airways, there is also evidence of the importance of peribronchial vascular inflammation and remodeling in its pathophysiology. Objectives To determine the effects of anti-IL-17 therapy on peribronchial vessels of an asthma model exacerbated by lipopolysaccharide. Methods We evaluated several factors, including lung function, inflammation, oxidative stress, vascular remodeling, and signaling pathways present in the peribronchial vessels of 66 male BALB/c mice exposed to ovalbumin and treated (or not) treated with anti-IL-17. Twenty-four hours before the end of the experimental protocol, groups of sensitized animals (OVA-LPS and OVA-LPS anti-IL-17) also received LPS. Results The OVA-LPS-anti-IL-17 group presented a decrease in several factors [airway resistance and elastance, bronchoalveolar lavage fluid (BALF) cell counts, inflammatory response, eosinophils, TSLP, IL-33, TARC, TNF-alpha, CD4+, CD8+, IL-4, IL-6, IL-10, IL-17, and VEGF positive cells/10(4)mu m(2), peribronchovascular edema, and angiogenesis], including remodeling (MMP-9, MMP-12, TIMP-1 and TGF-beta positive cells and volume fraction of collagen fibers I, collagen fibers III, collagen fibers V, decorin, lumican, actin, biglycan, fibronectin, and integrin), oxidative stress (iNOS positive cells and volume fraction of PGF2 alpha), and signaling pathways (FoxP3), as well as dendritic cells, NF-kB, ROCK-1, ROCK-2, STAT-1, and phosphor-STAT1-positive cells compared to OVA-LPS (p < 0.05). Conclusions In this model of LPS-induced asthma exacerbation, IL-17 inhibition represents a promising therapeutic strategy, indicating the potential of bronchial vascular control of Th2 and Th17 responses and the activation of the remodeling and oxidative stress pathways, associated with the control of signaling pathways.
conferenceObject Does Treatment with a Plant Proteinase Inhibitor, Enterolobium Contortisiliquum Contribute to the Control of Inflammation, Remodeling and Oxidative Stress in Mice with Asthma-COPD Overlap (ACO)?(2022) CAMARGO, L.; BARBOSA, J.; SILVA, L.; JOAO, J.; SANTOS, H.; SARAIVA-ROMANHOLO, B.; FUKUZAKI, S.; BEZERRA, S.; PRADO, C.; LOPES, F.; OLIVA, M.; RIGHETTI, R.; LEICK, E.; TIBERIO, I.- Effects of a Peptide Derived from the Primary Sequence of a Kallikrein Inhibitor Isolated from Bauhinia bauhinioides (pep-BbKI) in an Asthma-COPD Overlap (ACO) Model(2023) SILVA, Luana Laura Sales da; BARBOSA, Jessica Anastacia Silva; JOAO, Juliana Morelli Lopes Goncalves; FUKUZAKI, Silvia; CAMARGO, Leandro do Nascimento; SANTOS, Tabata Maruyama dos; CAMPOS, Elaine Cristina de; COSTA, Arthur Silva; SARAIVA-ROMANHOLO, Beatriz Mangueira; BEZERRA, Suellen Karoline Moreira; LOPES, Fernanda Tenorio Quirino dos Santos; BONTURI, Camila Ramalho; OLIVA, Maria Luiza Vilela; LEICK, Edna Aparecida; RIGHETTI, Renato Fraga; TIBERIO, Iolanda de Fatima Lopes Calvo(1) There are several patients with asthma-COPD overlap (ACO). A peptide derived from the primary sequence of a kallikrein inhibitor isolated from Bauhinia bauhinioides (pep-BbKI) has potent anti-inflammatory and antioxidant effects. Purpose: To investigate the effects of pep-BbKI treatment in an ACO model and compare them with those of corticosteroids. (2) BALB/c mice were divided into groups: SAL (saline), OVA (ovalbumin), ELA (elastase), ACO (ovalbumin + elastase), ACO-pep-BbKI (treated with inhibitor), ACO-DX (dexamethasone treatment), ACO-DX-pep-BbKI (both treatments), and SAL-pep-BbKI (saline group treated with inhibitor). We evaluated: hyperresponsiveness to methacholine, bronchoalveolar lavage fluid (BALF), exhaled nitric oxide (eNO), IL-1 & beta;, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17, IFN-& gamma;, TNF-& alpha;, MMP-9, MMP-12, TGF-& beta;, collagen fibers, iNOS, eNO, linear mean intercept (Lm), and NF-& kappa;B in airways (AW) and alveolar septa (AS). (3) ACO-pep-BbKI reversed ACO alterations and was similar to SAL in all mechanical parameters, Lm, neutrophils, IL-5, IL-10, IL-17, IFN-& gamma;, TNF-& alpha;, MMP-12 (AW), collagen fibers, iNOS (AW), and eNO (p > 0.05). ACO-DX reversed ACO alterations and was similar to SAL in all mechanical parameters, Lm, total cells and differentials, IL-1 & beta;(AS), IL-5 (AS), IL-6 (AS), IL-10 (AS), IL-13 (AS), IFN-& gamma;, MMP-12 (AS), TGF-& beta; (AS), collagen fibers (AW), iNOS, and eNO (p > 0.05). SAL was similar to SAL-pep-BbKI for all comparisons (p > 0.05). (4) Pep-BbKI was similar to dexamethasone in reducing the majority of alterations of this ACO model.
conferenceObject Plant Protease Inhibitors in Mice ACO Model: Comparison With Corticosteroid(2023) JOAO, J.; BARBOSA, J. A.; SILVA, L. L.; FUKUZAKI, S.; CAMARGO, L. D.; BEZERRA, S. K.; CAMPOS, E. C.; BONTURI, C.; LOPES, F. D.; OLIVA, M. V.; RIGHETTI, R. F.; TIBERIO, I. D.; LEICK, E. A.conferenceObject Plant Protease Inhibitors Had an Effect on Controlling Lung Inflammation, Remodeling and Oxidative Stress in Mice with ASTHMA-COPD Overlap: Comparison with Corticosteroid(2022) RIGHETTI, R. F.; JOAO, J.; BARBOSA, J.; SILVA, L.; FUKUZAKI, S.; CAMARGO, L.; SARAIVA-ROMANHOLO, B.; BEZERRA, S.; PRADO, C. M.; LOPES, F. D.; OLIVA, M.; LEICK, E. A.; TIBERIO, I. F. L. C.